Clinical Trial: CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07234110) titled 'CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors' on Nov. 14.

Brief Summary: This is an investigator-initiated dose-finding clinical study with the primary objective of evaluating the safety of CD5CART in the treatment of subjects with relapsed and refractory CD5 hematological malignancies and to explore the MTD of CD5CART treatment of relapsed and refractory subjects with CD5 hematological malignancies. At the same time, the effectiveness and pharmacokinetic characteristics of CD5CART treatment of relapsed and refractory CD5 hematological tumors in subjects were explored

Study Start Date: Sept. 03

St...